Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.21.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:        
Research and development $ 3,840,399 $ 1,302,515 $ 7,706,407 $ 2,710,663
General and administrative 2,196,632 1,208,374 4,194,617 2,269,280
Loss from operations (6,037,031) (2,510,889) (11,901,024) (4,979,943)
Foreign exchange gain (loss) (2,076) 14,142 (15,323) 14,142
Net loss $ (6,039,107) $ (2,496,747) $ (11,916,347) $ (4,965,801)
Share information:        
Net loss per share, basic and diluted $ (0.32) $ (0.44) $ (0.66) $ (0.88)
Weighted average shares outstanding, basic and diluted 18,742,926 5,719,988 17,972,329 5,655,591